Animal Health Partnering
Animal Health Partnering
Search
Metabolic Diseases
Metabolic Diseases
Therapeutics
Therapeutics
Human Health Partnering
Human Health Partnering
Science Focus
Science Focus
Human Health Partnering Connect with Us
Human Health Partnering Connect with Us
Our Stories
Find out more about us by reading our stories. Below are the latest press releases, news stories, and more from our family around the world.
Privacy Notice
Privacy Notice
NASH
NASH
Ruminants
Ruminants
Corporate Profile
Corporate Profile
Heart Diseases
Heart Diseases
Boehringer Ingelheim unites dermatologists to discuss the management of Generalized Pustular Psoriasis (GPP)
The ‘GPP Summit, discussed latest research and advances in the management of GPP to help improve patient outcomes across Saudi Arabia, and the United Arab Emirates.
Research and Development Pipeline
Find out more about our human pharma research and development pipeline
240415_BI_APC_Infographic_ENG.pdf
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
In 2023, Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 779 million, reflecting a 13% increase compared to the previous year.
Imprint
Imprint
Ilda Naccour
Elevating Cardio-Renal-Metabolic Care: Boehringer Ingelheim Imparts Latest Insights to 400 Regional Experts
Boehringer Ingelheim hosted the ‘CRM Summit’ to facilitate exchanges and discussions on the latest advances in the management of cardiovascular, renal, and metabolic diseases to help improve patient outcomes across India, the Middle East and Africa
The UAE MOHAP Approves the First and Only Therapy for the Treatment of Adult Generalized Pustular Psoriasis Flares
The first treatment of its kind in the UAE by Boehringer Ingelheim is the only FDA and EMA-approved medication used to treat GPP flares in adult patients and works to help block a source of inflammation that may cause GPP flares
Boehringer Ingelheim and Alpha Pharma Collaborate to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia
Boehringer Ingelheim is driving localization capacities with robust partnerships in alignment with Vision 2030
Boehringer Ingelheim launches the First Approved Treatment for Idiopathic Pulmonary Fibrosis in Algeria
Nintedanib is the only treatment for Idiopathic Pulmonary Fibrosis approved by the Algerian Ministry of Health
History
Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim.
Corporate Factsheet 2024
More Green
More Green